Overview
Josep Capdevila-Morell practices practicing medicine in Barcelona, Spain.
His clinical expertise encompasses Methicillin-Resistant Staphylococcus Aureus (MRSA).
He is actively involved in clinical research, co-authoring 10 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Josep A. Capdevila-Morell
Is Josep A. Capdevila-Morell a top-rated expert for Methicillin-Resistant Staphylococcus Aureus (MRSA)?
MediFind is an objective health platform that identifies experts based on real-world data. Josep A. Capdevila-Morell is classified as an Experienced expert for Methicillin-Resistant Staphylococcus Aureus (MRSA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Josep A. Capdevila-Morell participate in research or clinical trials?
Yes. Josep A. Capdevila-Morell has published 10 articles and abstracts on conditions like Methicillin-Resistant Staphylococcus Aureus (MRSA). You can view a list of Josep A. Capdevila-Morell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Methicillin-Resistant Staphylococcus Aureus (MRSA)Mr. Capdevila-Morell isExperienced. Learn about Methicillin-Resistant Staphylococcus Aureus (MRSA).